[Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Two multiple myeloma (MM) patients developed venous thromboembolism (VTE) while being treated with lenalidomide and low-dose dexamethasone. Aspirin is recommended for VTE prophylaxis when using lenalidomide/dexamethasone for MM patients with a standard risk of VTE. Despite aspirin administration, however, these two patients experienced VTE. Following VTE development, warfarin and then a Factor Xa inhibitor, edoxaban, were administered. The edoxaban treatment, especially, resulted in favorable and effective control of VTE. Considering these observations, Factor Xa inhibitors may in future become a preferred option for prevention and treatment of VTE when managing MM patients.
Department of Internal Medicine, JCHO Tokyo Kamata Medical Center.
Masato
M
Kawaguchi
Norio
N
Uchimura
Yuko
Y
Okuda
Satomi
S
Konuma
Yoshio
Y
Nehashi
D000368:Aged; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000000981:diagnostic imaging* / Q000188:drug therapy; D011725:Pyridines / Q000627:therapeutic use*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D054556:Venous Thromboembolism / Q000188:drug therapy*
D065427:Factor Xa Inhibitors; D011725:Pyridines; D013844:Thiazoles; D013792:Thalidomide; D000077269:Lenalidomide; C552171:edoxaban